全基因测序市场－全球产业规模、份额、趋势、机会及预测（依产品/服务、类型、工作流程、应用、最终用户、地区和竞争格局划分），2021-2031年

全球全基因测序市场预计将从 2025 年的 21.8 亿美元成长到 2031 年的 45.1 亿美元，复合年增长率为 12.88%。

全基因测序(WGS) 是一种综合性的实验室技术，它能够在一次实验中解码生物体的全部 DNA 序列，包括编码区和非编码区。该领域的发展主要得益于定序成本的大幅下降以及对精准医疗日益增长的需求，以改善肿瘤和罕见遗传疾病的诊断。例如，英国生物银行于 2025 年成功完成了对约 490,640 名参与者全基因组序列的全面分析，展现了大规模人群基因组分析所需的扩充性。

然而，市场发展面临的主要障碍在于处理和储存高Petabyte系统产生的大量数据所面临的挑战。分析、保存和解读PB级基因组数据需要先进的计算基础设施，这造成了经济和技术上的障碍，限制了其在资源有限的临床环境中的广泛应用。

市场驱动因素

定序成本和耗材的大幅下降是市场扩张的关键驱动力，使得高通量定序平台能够惠及专业研究机构以外的机构。定序技术的进步推动了价格的快速下降，使实验室能够从标靶基因检测过渡到全基因组分析工作流程，从而降低营运成本并获得更优的诊断结果。根据2025年2月题为「Ultima Genomics生产力提升超过50%」的新闻稿，UG 100 Solaris系统的商业化发布将定序成本降低至每百万reads 0.24美元，从而有效地实现了每read 80美元的基因组分析成本。价格的下降降低了临床应用的经济门槛，使医疗系统能够在不牺牲准确性或覆盖深度的前提下，将全面的基因组分析纳入癌症和遗传疾病的标准诊断流程。

同时，政府主导的人口定序计划的兴起，对大规模定序能力的需求也显着成长。各国正大力投资国家生物银行项目，以收集多样化的遗传讯息，加速药物研发，并推动精准医疗在不同族群的应用。 2025年2月，美国国立卫生研究院（NIH）在一份题为“‘我们所有人’计划参与者数据扩充50%以上”的新闻稿中宣布，其研究数据集已扩展至包含超过63.3万名个体的详细资讯，凸显了联邦政府授权下数据生成的规模之大。这一趋势在全球普遍存在，各国都在努力招募不同人群参与纵贯研究。例如，「我们的未来健康」计画在2025年达到了250万志愿者的里程碑，进一步显示了国家基因组资源在生物医学研究领域的快速扩张。

市场挑战

管理和储存海量基因组数据的巨大挑战目前是全球全基因测序市场的主要阻碍因素。虽然产生原始资料的成本有所下降，但处理、储存和保护这些资料所需的下游生物资讯学基础设施的相关费用却不断增加。因此，出现了一个严重的瓶颈：DNA定序的技术能力已经超过了有效维护所产生资料集的能力，这使得小规模的医疗机构难以利用这些技术。

根据全球基因组健康联盟 (GA4GH) 发布的《2025 年展望》报告，其相关基础设施技术支援处理超过 10 Petabyte的基因组数据。如此大规模的资讯处理需要企业级储存系统和高效能运算环境，而这些成本对于资源有限的临床机构而言往往难以承受。因此，资料管理所需的大量资本和营运成本直接阻碍了全基因组定序在标准临床环境中的广泛应用，并将市场扩张主要限制在资金雄厚的研究中心。

市场趋势

将人工智慧 (AI) 整合到基因组数据分析中，正从根本上改变生物资讯流程，以 GPU 加速架构取代传统的基于 CPU 的工作流程。这项转变解决了二次分析中的一个关键瓶颈：变异检测和比对的速度历来慢于原始资料产生速度。深度学习演算法的应用使实验室能够以惊人的速度分析序列读段，从而实现近乎即时的诊断结论，这对于紧急临床诊疗至关重要。例如，NVIDIA 在 2024 年 11 月发表的论文《利用加速泛基因组比对发现新的生物学见解》中指出，其 Parabricks v4.4 软体在单一 GPU 系统上实现了端到端 30 倍全基因组定序分析，耗时缩短不到 30 分钟，显着缩短了从样本采集到获得结果的时间。

同时，市场正大幅增加混合定序和长读长定定序技术的应用，以解决标准短读长定序平台难以分析的复杂基因组区域。研究人员正利用长读长定序技术，透过详细揭示结构变异、大片段插入和重复序列，有效地填补参考基因组序列的空白，从而提高罕见疾病的诊断准确性。高通量长读长定序系统的快速普及，突破了传统方法的限制，提供了全基因组的可视性，也印证了这项技术进步。根据Pacific Biosciences于2025年1月发布的最新2024年度报告，该公司定序仪的数据输出量在2024年增长了81%，显示先进基因组研究对高品质定序数据的需求日益增长。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球全基因测序市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依产品/服务（设备、耗材、服务）分类
  • 按类型（大规模全基因测序、小规模全基因测序）
  • 依工作流程（序列预处理、定序、资料分析）
  • 依应用领域（人类全基因测序、植物全基因测序、动物全基因测序、微生物全基因测序）
  • 按最终用户（学术/研究机构、医院/诊所、製药/生技公司、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美全基因测序市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲全基因测序市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区全基因测序市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲全基因测序市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲全基因测序市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

13. 全球全基因测序市场：SWOT 分析

第十四章 波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• Oxford Nanopore Technologies plc.
• Pacific Biosciences of California, Inc.
• BGI Group
• QIAGEN NV
• Agilent Technologies, Inc.
• ProPhase Labs, Inc.
• Psomagen, Inc
• Azenta US Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Whole Genome Sequencing Market is projected to expand from USD 2.18 Billion in 2025 to USD 4.51 Billion by 2031, registering a CAGR of 12.88%. Whole Genome Sequencing (WGS) serves as an exhaustive laboratory technique that deciphers an organism's entire DNA sequence, encompassing both coding and non-coding areas within a single process. Growth in this sector is largely underpinned by the dramatic decrease in sequencing expenses and the escalating need for precision medicine to enhance oncology and rare genetic disorder diagnostics. For example, the UK Biobank successfully coordinated the thorough analysis of whole genome sequences for roughly 490,640 participants in 2025, highlighting the scalability necessary for extensive population genomics.

Nevertheless, a major obstacle hindering market progression is the difficulty associated with handling and archiving the colossal amounts of data produced by high-throughput systems. The necessity for sophisticated computational infrastructure to analyze, secure, and interpret petabytes of genomic data imposes a financial and technical hurdle that limits widespread implementation in clinical environments with constrained resources.

Market Driver

The significant reduction in sequencing costs and consumables acts as a major driver for market expansion, making high-throughput platforms accessible to facilities other than exclusive research institutes. Advancements in sequencing architecture are rapidly lowering prices, permitting laboratories to transition from targeted panels to whole genome workflows, thereby attaining superior diagnostic results at reduced operational costs. According to a February 2025 press release titled 'Ultima Genomics Increases Output by Over 50%', the commercial introduction of the UG 100 Solaris system reduced sequencing costs to $0.24 per million reads, effectively facilitating an $80 genome. This trend of falling prices lowers the financial threshold for clinical implementation, enabling healthcare systems to incorporate thorough genomic profiling into standard diagnostics for oncology and genetic diseases without sacrificing accuracy or coverage depth.

Simultaneously, the increase in government-sponsored population genomics projects is creating significant demand for extensive sequencing capabilities. Countries are making substantial investments in national biobanking initiatives to gather diverse genetic information, which hastens drug development and the application of precision medicine across various demographic groups. In February 2025, the National Institutes of Health announced in 'All of Us Adds Data from 50% More Participants' that the program had broadened its research dataset to encompass details from over 633,000 participants, highlighting the immense scale of data generation mandated by federal directives. This pattern is observed worldwide as initiatives strive to enlist diverse groups for longitudinal research; for example, Our Future Health achieved a milestone of 2.5 million volunteers in 2025, further demonstrating the swift growth of national genomic resources for biomedical study.

Market Challenge

The formidable task of administering and archiving vast quantities of genomic data currently serves as a major constraint on the Global Whole Genome Sequencing Market. Although the expense of producing raw sequence data has decreased, the costs linked to the downstream bioinformatic infrastructure required to process, store, and protect this data have increased. This results in a substantial bottleneck where the technical ability to sequence DNA exceeds the capacity to efficiently maintain the generated datasets, thereby stopping smaller healthcare institutions from utilizing these technologies.

As reported by the Global Alliance for Genomics and Health in 2025, the organization's associated infrastructure technologies supported the processing of over 10 petabytes of genomic data. Handling information of this magnitude demands enterprise-grade storage systems and high-performance computing environments, which are frequently too costly for clinical settings with limited resources. Consequently, the significant capital and operational expenses necessary for data stewardship directly impede the wider adoption of whole genome sequencing in standard medical practice, restricting market expansion primarily to well-financed research hubs.

Market Trends

The incorporation of Artificial Intelligence for Genomic Data Analysis is fundamentally transforming bioinformatic processes by substituting traditional CPU-based workflows with accelerated GPU-focused architectures. This transition tackles the crucial bottleneck of secondary analysis, where the pace of variant calling and alignment has traditionally been slower than raw data generation. By employing deep learning algorithms, laboratories can now analyze sequence reads with exceptional speed, allowing for near real-time diagnostic conclusions that are vital for urgent clinical care. For instance, NVIDIA announced in November 2024 via their 'Discover New Biological Insights with Accelerated Pangenome Alignment' release that their Parabricks v4.4 software accomplished end-to-end 30x whole genome sequencing analysis in under 30 minutes on a single-GPU system, drastically reducing the time from sample collection to results.

Concurrently, the market is observing a significant shift toward the Adoption of Hybrid and Long-Read Sequencing Technologies to address complex genomic areas that standard short-read platforms cannot access. Researchers are increasingly leveraging long-read abilities to thoroughly define structural variants, large insertions, and repetitive elements, effectively bridging gaps in reference assemblies and enhancing diagnostic outcomes for rare diseases. This technical progression is demonstrated by the swift adoption of high-throughput long-read systems that offer full genomic visibility surpassing legacy method limitations; according to Pacific Biosciences' January 2025 '2024 Annual Report' update, data output from the company's sequencers increased by 81% in 2024, indicating growing demand for high-fidelity reads in advanced genomic research.

Key Market Players

• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• Oxford Nanopore Technologies plc.
• Pacific Biosciences of California, Inc.
• BGI Group
• QIAGEN N.V.
• Agilent Technologies, Inc.
• ProPhase Labs, Inc.
• Psomagen, Inc
• Azenta US Inc.

Report Scope

In this report, the Global Whole Genome Sequencing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Whole Genome Sequencing Market, By Product & Service

• Instruments
• Consumables
• Services

Whole Genome Sequencing Market, By Type

• Large Whole Genome Sequencing
• Small Whole Genome Sequencing

Whole Genome Sequencing Market, By Workflow

• Pre-sequencing
• Sequencing
• Data Analysis

Whole Genome Sequencing Market, By Application

• Human Whole Genome Sequencing
• Plant Whole Genome Sequencing
• Animal Whole Genome Sequencing
• Microbial Whole Genome Sequencing

Whole Genome Sequencing Market, By End User

• Academic & Research Institutes
• Hospitals & Clinics
• Pharmaceutical & Biotechnology Companies
• Others

Whole Genome Sequencing Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Whole Genome Sequencing Market.

Available Customizations:

Global Whole Genome Sequencing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Whole Genome Sequencing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product & Service (Instruments, Consumables, Services)
  • 5.2.2. By Type (Large Whole Genome Sequencing, Small Whole Genome Sequencing)
  • 5.2.3. By Workflow (Pre-sequencing, Sequencing, Data Analysis)
  • 5.2.4. By Application (Human Whole Genome Sequencing, Plant Whole Genome Sequencing, Animal Whole Genome Sequencing, Microbial Whole Genome Sequencing)
  • 5.2.5. By End User (Academic & Research Institutes, Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Others)
  • 5.2.6. By Region
  • 5.2.7. By Company (2025)
• 5.3. Market Map

6. North America Whole Genome Sequencing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product & Service
  • 6.2.2. By Type
  • 6.2.3. By Workflow
  • 6.2.4. By Application
  • 6.2.5. By End User
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Whole Genome Sequencing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product & Service
      • 6.3.1.2.2. By Type
      • 6.3.1.2.3. By Workflow
      • 6.3.1.2.4. By Application
      • 6.3.1.2.5. By End User
  • 6.3.2. Canada Whole Genome Sequencing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product & Service
      • 6.3.2.2.2. By Type
      • 6.3.2.2.3. By Workflow
      • 6.3.2.2.4. By Application
      • 6.3.2.2.5. By End User
  • 6.3.3. Mexico Whole Genome Sequencing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product & Service
      • 6.3.3.2.2. By Type
      • 6.3.3.2.3. By Workflow
      • 6.3.3.2.4. By Application
      • 6.3.3.2.5. By End User

7. Europe Whole Genome Sequencing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product & Service
  • 7.2.2. By Type
  • 7.2.3. By Workflow
  • 7.2.4. By Application
  • 7.2.5. By End User
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Whole Genome Sequencing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product & Service
      • 7.3.1.2.2. By Type
      • 7.3.1.2.3. By Workflow
      • 7.3.1.2.4. By Application
      • 7.3.1.2.5. By End User
  • 7.3.2. France Whole Genome Sequencing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product & Service
      • 7.3.2.2.2. By Type
      • 7.3.2.2.3. By Workflow
      • 7.3.2.2.4. By Application
      • 7.3.2.2.5. By End User
  • 7.3.3. United Kingdom Whole Genome Sequencing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product & Service
      • 7.3.3.2.2. By Type
      • 7.3.3.2.3. By Workflow
      • 7.3.3.2.4. By Application
      • 7.3.3.2.5. By End User
  • 7.3.4. Italy Whole Genome Sequencing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product & Service
      • 7.3.4.2.2. By Type
      • 7.3.4.2.3. By Workflow
      • 7.3.4.2.4. By Application
      • 7.3.4.2.5. By End User
  • 7.3.5. Spain Whole Genome Sequencing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product & Service
      • 7.3.5.2.2. By Type
      • 7.3.5.2.3. By Workflow
      • 7.3.5.2.4. By Application
      • 7.3.5.2.5. By End User

8. Asia Pacific Whole Genome Sequencing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product & Service
  • 8.2.2. By Type
  • 8.2.3. By Workflow
  • 8.2.4. By Application
  • 8.2.5. By End User
  • 8.2.6. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Whole Genome Sequencing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product & Service
      • 8.3.1.2.2. By Type
      • 8.3.1.2.3. By Workflow
      • 8.3.1.2.4. By Application
      • 8.3.1.2.5. By End User
  • 8.3.2. India Whole Genome Sequencing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product & Service
      • 8.3.2.2.2. By Type
      • 8.3.2.2.3. By Workflow
      • 8.3.2.2.4. By Application
      • 8.3.2.2.5. By End User
  • 8.3.3. Japan Whole Genome Sequencing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product & Service
      • 8.3.3.2.2. By Type
      • 8.3.3.2.3. By Workflow
      • 8.3.3.2.4. By Application
      • 8.3.3.2.5. By End User
  • 8.3.4. South Korea Whole Genome Sequencing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product & Service
      • 8.3.4.2.2. By Type
      • 8.3.4.2.3. By Workflow
      • 8.3.4.2.4. By Application
      • 8.3.4.2.5. By End User
  • 8.3.5. Australia Whole Genome Sequencing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product & Service
      • 8.3.5.2.2. By Type
      • 8.3.5.2.3. By Workflow
      • 8.3.5.2.4. By Application
      • 8.3.5.2.5. By End User

9. Middle East & Africa Whole Genome Sequencing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product & Service
  • 9.2.2. By Type
  • 9.2.3. By Workflow
  • 9.2.4. By Application
  • 9.2.5. By End User
  • 9.2.6. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Whole Genome Sequencing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product & Service
      • 9.3.1.2.2. By Type
      • 9.3.1.2.3. By Workflow
      • 9.3.1.2.4. By Application
      • 9.3.1.2.5. By End User
  • 9.3.2. UAE Whole Genome Sequencing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product & Service
      • 9.3.2.2.2. By Type
      • 9.3.2.2.3. By Workflow
      • 9.3.2.2.4. By Application
      • 9.3.2.2.5. By End User
  • 9.3.3. South Africa Whole Genome Sequencing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product & Service
      • 9.3.3.2.2. By Type
      • 9.3.3.2.3. By Workflow
      • 9.3.3.2.4. By Application
      • 9.3.3.2.5. By End User

10. South America Whole Genome Sequencing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product & Service
  • 10.2.2. By Type
  • 10.2.3. By Workflow
  • 10.2.4. By Application
  • 10.2.5. By End User
  • 10.2.6. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Whole Genome Sequencing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product & Service
      • 10.3.1.2.2. By Type
      • 10.3.1.2.3. By Workflow
      • 10.3.1.2.4. By Application
      • 10.3.1.2.5. By End User
  • 10.3.2. Colombia Whole Genome Sequencing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product & Service
      • 10.3.2.2.2. By Type
      • 10.3.2.2.3. By Workflow
      • 10.3.2.2.4. By Application
      • 10.3.2.2.5. By End User
  • 10.3.3. Argentina Whole Genome Sequencing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product & Service
      • 10.3.3.2.2. By Type
      • 10.3.3.2.3. By Workflow
      • 10.3.3.2.4. By Application
      • 10.3.3.2.5. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Whole Genome Sequencing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Illumina, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Thermo Fisher Scientific Inc.
• 15.3. Oxford Nanopore Technologies plc.
• 15.4. Pacific Biosciences of California, Inc.
• 15.5. BGI Group
• 15.6. QIAGEN N.V.
• 15.7. Agilent Technologies, Inc.
• 15.8. ProPhase Labs, Inc.
• 15.9. Psomagen, Inc
• 15.10. Azenta US Inc.

16. Strategic Recommendations

17. About Us & Disclaimer